MARCOS NAOYUKI SAMANO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
LIM/61 - Laboratório de Pesquisa em Cirurgia Torácica, Hospital das Clínicas, Faculdade de Medicina
LIM/61 - Laboratório de Pesquisa em Cirurgia Torácica, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
bookPart Via aérea em cirurgia torácica(2013) FERNANDES, Lucas Matos; SAMANO, Marcos Naoyuki- Internationalization of universities: the need to navigate in foreign waters(2013) MARIANI, Alessandro Wasum; PEGO-FERNANDES, Paulo Manuel; SAMANO, Marcos NaoyukiInternacionalização das universidades: a necessidade de navegar em águas estrangeiras
- THE HEART INSTITUTE LUNG TRANSPLANT REGISTRY: REPORT OF RESULTS FROM 2003 TO 2012(2013) CARAMORI, M. L.; FERNANDES, L. M.; AFONSO JUNIOR, J. E.; TEIXEIRA, R. O. B.; CAMPOS, S. V.; CARRARO, R. M.; SAMANO, M. N.; PEGO-FERNANDES, P. M.; JATENE, F. B.OBJECTIVE: The aim of this study was to analyze the outcome of patients who underwent lung transplantation at a single center over a 9 yr period. INTRODUCTION: Lung diseases comprise a heterogeneous group of patients which may lead to end stage lung disease and referral for lung transplantation. This procedure has become a therapeutic option for patients with advanced pulmonary diseases due to improvements in organ conservation, surgical technique, immunosuppressive therapy and treatment of post-operative infections.METHODS: A retrospective study using chart review collected data was performed on all patients transplanted between August, 2003 and August, 2012 at The Heart Institute, São Paulo, Brazil. Multiple pre-transplant characteristics and post-transplant survival were analyzed. RESULTS:During 9 yrs we performed 157 lung transplants; 118 (75%) patients underwent bilateral and 39 (25%) single lung transplant. The most common indication was COPD (24.2%), followed by Cystic Fibrosis (23.5%), Pulmonary Fibrosis (18.4%), Bronchiectasis (19%), Lymphangioleiomyomatosis (4.4%) and others diseases (10%). A total of 146 lung transplants were performed on patients over the age of 18 yrs. Two patients were less than 12 yrs of age and nine were between 12 to 18 yrs old. The overall 1, 3, 5- and 7-yr survivals were 71.3%, 65%, 63% and 58%, respectively. Among the pediatric and adolescent group the most frequent cause for lung transplantation was cystic fibrosis. There was only one death in this young group of patients. CONCLUSION: These findings confirm the consolidated status of lung transplant in our institution as a therapeutic option for advanced chronic respiratory disease, both in young group as well in adults.
- Lung Transplantation in Patients With Cystic Fibrosis(2013) SAMANO, M. N.; PEGO-FERNANDES, P. M.; RIBEIRO, A. K. Fonseca; TURACA, K.; ABDALLA, L. G.; FERNANDES, L. M.; CORREIA, A. T.; JATENE, F. B.Cystic fibrosis (CF) an autosomal recessive genetic disorder, affects many organs. The great majority of deaths occur due to respiratory failure after many years of chronic pulmonary infection. Despite recent progress in early detection by studies of genetic mutations and better understanding to treat nutritional and infectious states, lung transplantation is the CF treatment for most advanced cases. According to the International Society for Heart and Lung Transplantation (ISHLT) data, CF is the third most common reason for lung transplantation (16.8%) showing the best survival rate (60% at 5 years). We have described our experience in lung transplantation of CF patients between January 2000 and December 2011, reviewing medical charts of these patients were for gender, age, body mass index (BMI), comorbidities, disease duration, previous sputum gram stain, ischemic time, incidence of severe primary graft dysfunction (PGD Grade 3), intensive care unit (ICU) length of stay, and Kaplan-Meier survival. Among 150 lung transplantation, the 30 CF patients (20%) represented the second most common cause. The average age was 27.4 +/- 9.2 years, with a slight predominance of males (n = 16; 53.3%). The average BMI was 18.9 +/- 2.6. Most patients (60%) had pancreatic exocrine dysfunction. Also, 83.3% of patients showed a positive sputum culture for Pseudomonas, while Burkholderia cepacia was identified in only 4 patients (13.3%). The average time of the disease was 20.8 +/- 9.7 years. All transplantation were bilateral with an average ischemic time of 472 +/- 98.3 minutes and ICU length of stay of 9.9 +/- 6.3 days. The survival rates at 1 and 5 years were 92% and 77%, respectively, corresponding to the best outcomes among underlying diseases, comparable with other worldwide series and better than the ISHLT reports. CF, the second most common cause for lung transplantation among our cases, showed the best survival rate among all causes. Our survival rate was comparable with other reports.